Pharmaceutical Contract Manufacturing in India

A trusted pharmaceutical contract manufacturing services provider in India for compliant third party manufacturing, regulatory support and global pharmaceutical supply through certified manufacturing networks.

Request a Quote Find Medicines
  • Established 2003 | ISO 9001:2015 certified | WHO-GSDP certified | Supply to 180+ countries
Pharmaceutical contract manufacturing in India, cGMP certified partner facility producing sterile injectables and oral formulations, coordinated by GNH India

GNH India Pharmaceuticals Limited is not a manufacturer. It is a pharmaceutical contract manufacturing services provider in India, coordinating compliant third party manufacturing, regulatory support and global pharmaceutical supply through certified manufacturing networks. The company provides structured pharma contract manufacturing services for pharmaceutical companies seeking reliable manufacturing partners, regulatory guidance and global supply capabilities. This page sets out what those services cover, the dosage forms and facility approvals available across the partner network, how a contract manufacturing programme is coordinated from specification through to delivery, the compliance frameworks GNH India operates under, and the answers to the questions buyers most often raise about contract manufacturing pharma India programmes.

Through a carefully selected network of certified manufacturing partners, GNH India supports the development, manufacturing and supply of pharmaceutical products aligned with regulatory standards and market requirements. Each programme is matched to the partner facility whose approvals, dosage form capability and batch scale fit the brief, and GNH India retains coordination of the regulatory documentation and export handling that follows production. Established in 2003, the company has supplied pharmaceutical products to more than 180 countries.

These pharma contract manufacturing services are designed for pharmaceutical companies, global supply partners and healthcare organisations seeking compliant third party manufacturing solutions. GNH India works only with licensed businesses and does not sell consumer medicines or operate retail pharmacies.

Manufacturing Capabilities Across the Partner Network

The partner network is multi site rather than single plant. It includes cGMP certified plants for chemical synthesis, a fully equipped pilot plant, and dedicated formulation and packaging lines. That spread allows a sterile injectable programme and a high volume oral solid programme to be quoted from the same enquiry, which is a practical advantage when a buyer is sourcing more than one presentation of the same product.

Dosage forms and product types

  • Active pharmaceutical ingredients and intermediates
  • Sterile injectables, including vials and ampoules
  • Solid oral formulations such as tablets and capsules
  • Liquid oral formulations
  • Branded generics and true generics
  • Vaccines
  • Neutral label and private label pharmaceutical products

Facility approvals within the network

  • WHO-GMP approved manufacturing facilities
  • US FDA approved manufacturing facilities
  • UK MHRA approved manufacturing facilities
  • cGMP certified chemical synthesis plants
  • Pilot plant for development and scale up batches
  • Dedicated formulation and packaging lines

Facility selection is made per programme. Not every approval applies to every site, so GNH India confirms the specific facility and its current approval status at quotation stage. Batch scale runs from small pilot quantities for development and clinical supply through to multi-tonne commercial production, and minimum order quantities vary accordingly by product and process stage.

How Contract Manufacturing for Pharmaceuticals Is Coordinated

Contract manufacturing in the pharmaceutical industry in India follows a defined sequence. GNH India manages each stage on the buyer's behalf, from the first specification through to landed goods in the destination market.

Product requirement assessment

GNH India reviews the molecule, dosage form, strength, indicative volume, regulatory considerations and target market, and confirms whether the programme is feasible within the partner network before anything else proceeds.

Partner manufacturer identification

The facility whose approvals, equipment and batch scale suit the programme is identified, and its regulatory status is confirmed against the authority the buyer intends to register with.

Regulatory documentation and compliance coordination

Quality agreements, product specifications, artwork requirements and the regulatory document set are agreed before production is scheduled, so nothing has to be reconstructed after the fact. Documentation is prepared against CDSCO, FDA and EMA guidelines alongside country specific import requirements.

Manufacturing oversight and quality coordination

Production runs to the agreed batch record with in process controls, release testing and documentation traceability maintained throughout. Deviations are handled through documented change control.

Global supply and export support

Once the product is manufactured, GNH India prepares the export documentation and coordinates shipment under WHO-GSDP conditions, with temperature controlled and validated packaging where the product requires it.

Why Buyers Choose GNH India for Contract Manufacturing Pharma India Programmes

  • Manufacturing coordination and supply under one relationship. Most contract manufacturers stop at the factory gate. GNH India holds the manufacturing coordination and the export function together, so the same team that placed the programme handles documentation, compliance and delivery into the destination market.
  • Facility choice rather than facility constraint. Because GNH India does not own a plant, each programme is matched to the most appropriate partner site. A single site manufacturer has to make the product fit its existing lines.
  • Regulatory documentation handled in house. GNH India prepares CTD and eCTD dossiers, runs stability studies and supports BA and BE studies, so programmes needing registration support are not split across two vendors.
  • Over two decades in global pharmaceutical trade. Established in 2003, with supply to more than 180 countries across specialty, orphan, hard to find and cold chain product lines.

Regulatory and Compliance Information

GNH India coordinates manufacturing, sourcing and supply activity under the following frameworks:

  • WHO Good Storage and Distribution Practices (WHO-GSDP)
  • ISO 9001:2015 certified quality management system
  • Licensed Pharmaceutical Wholesaler, issued by the State FDA, Maharashtra
  • Import Export Code, issued by the DGFT, Government of India
  • Pharmexcil membership
  • FIEO membership

All manufacturing coordination, sourcing and supply activities follow applicable pharmaceutical regulatory standards and international trade compliance requirements.

Frequently Asked Questions

Pharmaceutical contract manufacturing in India is the outsourcing of medicine production to a certified Indian manufacturing facility while the commissioning company keeps ownership of the product, the brand and the marketing authorisation. India is used heavily for this because of the density of WHO-GMP, US FDA and UK MHRA approved sites. GNH India coordinates these programmes across a network of certified partner facilities and does not operate manufacturing plants of its own.

No. GNH India is a pharma contract manufacturing services provider. Production is carried out by certified partner manufacturing facilities, while GNH India handles facility matching, regulatory documentation, quality coordination and export supply. This is why a buyer is not limited to the capabilities of a single plant.

Third party manufacturing pharma is an arrangement where a company sells a product under its own brand and licence but has it produced entirely by an external manufacturing facility. The facility supplies the capacity, the process and the compliance. The brand owner takes the finished product to market.

Contract manufacturing usually involves a formulation supplied or co-developed by the commissioning company, with process development and validation forming part of the work. Pharma 3rd party manufacturing usually applies an established formulation already held by the manufacturing partner. Third party arrangements move faster because the process exists, while contract manufacturing gives more control over the formulation itself. Buyers often use the terms interchangeably, so GNH India confirms which model is intended at enquiry stage.

The partner network covers active pharmaceutical ingredients and intermediates, sterile injectables, solid oral formulations such as tablets and capsules, liquid oral formulations, vaccines, branded generics, and neutral or private label pharmaceutical products. Capability is confirmed per programme, since not every partner site handles every dosage form.

Minimum order quantities vary by product and by process stage. Small pilot batches can be accommodated for development and clinical supply, and programmes scale up to multi-tonne commercial runs. Because MOQ depends on the dosage form, the equipment involved and the batch stage, the applicable figure is confirmed against the buyer's specification rather than published as a single number.

The network includes WHO-GMP, US FDA and UK MHRA approved facilities alongside cGMP certified plants for chemical synthesis. Documentation is prepared against CDSCO, FDA and EMA guidelines as well as the requirements of the destination market regulatory authority. The specific site and its current approval status are confirmed at quotation stage.

Yes. Products can be supplied under the buyer's own brand or as neutral label presentations, with artwork adapted for the destination market. Packaging, labelling and artwork coordination form part of the programme.

Yes. GNH India has supplied pharmaceutical products to more than 180 countries since 2003. Manufacturing programmes are handled with export documentation, WHO-GSDP compliant handling and, where the product requires it, cold chain shipment with validated packaging.

Yes. The company prepares CTD and eCTD dossiers, conducts stability studies including for Zone IV conditions, and supports BA and BE studies for pharmaceuticals and biologicals. Buyers needing both manufacturing coordination and registration support do not have to split the programme across separate vendors.

Start Your Enquiry

Share the molecule, dosage form, strength, destination market and indicative volume, and the GNH India team will confirm feasibility and the applicable batch position.